News Center

2019

Release time：2019-03-06 02:19

It has completed Series D investment of approximtely USD45 million

Suzhou Kintor and CMAB Biopharma Inc. established strategic cooperation for the development and production of ALK-1 monoclonal antibody

The GT0486 (Detorsertib tablets) project has been approved for clinical trials in China

A phase II clinical trials of GT90001 (ALK-1 antibody) combined with PD-1 for liver cancer has been launched in Taiwan

The Group has signed a technical agreement with Peking University to in-license its c-Myc inhibitor project

Previous:

2020

Next:

2018

recommend News

Kintor